跳至主要内容
临床试验/NCT01192659
NCT01192659已完成不适用

Identification of Risk Factors for Low Lymphocyte Count in Patients With Type 2 Diabetes: An Analysis of Data From the SAVOR Study

AstraZeneca0 个研究点目标入组 16,492 人开始时间: 2010年5月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
AstraZeneca
入组人数
16,492
主要终点
To identify risk factors for lymphopenia, defined as an absolute lymphocyte count < 500 cells/μl, or investigator reported lymphopenia, in the SAVOR study population.

研究概览

简要总结

The purpose of this study is to identify risk factors for low lymphocyte count among patients with type 2 diabetes who are treated with oral antidiabetic drugs.

详细描述

Involving a secondary analysis of data collected prospectively from a defined cohort, for the SAVOR trial.

研究设计

研究类型
Observational
时间视角
Prospective

入排标准

年龄范围
40 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Enrolled in SAVOR
  • Diagnosed with T2DM
  • Baseline HbA1c ≥6.5% (based on the last measured and documented laboratory measurement within 6 months)
  • Age 40 or older
  • High risk for a cardiovascular event

排除标准

  • Not enrolled in SAVOR
  • Current or previous treatment with DPP4 inhibitors and/or GLP-1 or incretin mimetics.
  • Acute vascular event
  • Pregnancy
  • Severe autoimmune disease
  • Current chronic steroid use

结局指标

主要结局

To identify risk factors for lymphopenia, defined as an absolute lymphocyte count < 500 cells/μl, or investigator reported lymphopenia, in the SAVOR study population.

时间窗: 60 months

次要结局

  • To evaluate whether risk factors for low lymphocyte counts or decreasing lymphocyte count differ between saxagliptin users and non-users.(60 months)
  • To identify risk factors for decreased lymphocyte count (>=30% decrease from baseline.(60 months)
  • To identify risk factors for absolute lymphocyte count <750 cells/µl or investigator reported lymphopenia.(60 months)

研究者

发起方
AstraZeneca
申办方类型
Industry
责任方
Sponsor

相似试验